By Stephen Nakrosis

 

AbbVie Inc. on Monday said the European Commission approved Rinvoq to treat psoriatic arthritis and ankylosing spondylitis.

The company said Rinvoq, or upadacitinib, was approved to treat active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs.

Rinvoq was also indicated to treat active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy, AbbVie said.

The company said Rinvoq is the "first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis."

The company said approval was supported by data from three clinical studies which saw Rinvoq meeting all primary and key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

January 25, 2021 12:29 ET (17:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.